All News Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
41.31 ^USD	-0.94%		-1.95%	-2.57%

Mar. 25	Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	MT
Mar. 04	Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	Mar. 25	MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing	Mar. 04	MT
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 22	MT
AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions	Feb. 22	MT
Phew! The party continues!	Feb. 22
AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports	Feb. 21	RE
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
AbbVie CEO to Retire; COO Robert Michael Named Successor	Feb. 20	MT
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	Feb. 15	MT
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	Feb. 13	AN
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	Feb. 12	MT
AbbVie 4Q Sales Lower as Himura Revenue Sinks	Feb. 02	DJ
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	Feb. 02	RE
Neumora Therapeutics Names Kaya Pai Panandiker as Chief Commercial Officer	Jan. 22	MT
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders	Jan. 08	BU
Cerevel Therapeutics Holdings Insider Sold Shares Worth $424,700, According to a Recent SEC Filing	Dec. 28	MT
JPMorgan Raises Price Target on Cerevel Therapeutics Holdings to $45 From $25, Keeps Neutral Rating	Dec. 28	MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $331,608, According to a Recent SEC Filing	Dec. 27	MT
Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40	Dec. 22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

All News

Filters